

Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
14/LO/0259	134883	HRA Approval	RE-AKT: A randomised Phase II study of enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer	Yes	08/01/2018	01/07/2016	01/07/2017	30/06/2016	20/09/2017	08/09/2017	24/10/2017	Delay due to the allocation of Research Nurse	NHS Provider
17/LO/1652	233586	HRA Approval	CA209-9TW BMS Melanoma 1L Chart Review Study	Yes	16/03/2018	14/09/2017	11/09/2017	25/09/2017	04/12/2017	08/12/2017	08/12/2017	Sponsor queries in financial negotiations.	Sponsor
17/NW/0312	211974	HRA Approval	CaboGIST (EORTC 1317): Phase II study of cabozantinib in patients with metastatic gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib.	Yes	22/01/2018	10/05/2017	01/06/2017	13/07/2017	17/11/2017	24/11/2017	14/12/2017	Queries over patient pathway and funding queries.	Both
17/LO/0731	219463	HRA Approval	PIVOTAL BOOST: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost	Yes	04/01/2018	17/08/2017	17/08/2017	27/07/2017	14/12/2017	08/12/2017	02/01/2018	RTTQA delays in planning and set-up	NHS Provider
17/NE/0234	228388	HRA Approval	KEYNOTE 629: A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)	No		19/07/2017	19/07/2017	29/08/2017	01/12/2017	13/12/2017	01/02/2018	Sponsor delay - considerable sponsor contract and costing delays	Sponsor
	225049	HRA Approval	PS2: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NA?VE ADVANCED OR RECURRENT (STAGE IIIB NOT AMENABLE FOR MULTIMODALITY TREATMENT) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER WHO ARE DEEMED UNSUITABLE FOR PLATINUM-CONTAINING THERAPY	No		24/05/2017	27/07/2017	19/09/2017	18/01/2018	22/01/2018	05/02/2018	Sponsor delays - awaiting submission of substantial amendment plus costing queries	Sponsor
16/NW/0718	204299	HRA Approval	Respiratory Distress Symptom Intervention (RDSI)	No		22/09/2017	09/10/2017	15/06/2017	15/01/2018	15/01/2018	13/02/2018	Sponsor delay - sponsor took some time to greenlight CCC as a site	Sponsor
16/NE/0279	198051	HRA Approval	TIDAL: Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)	No		07/12/2017	21/12/2017	29/09/2016	14/02/2018	15/01/2018	15/02/2018	sub-contract delays from partner Trust	Neither
17/EM/0425	236800	HRA Approval	REALISM UK: Retrospective real world evidence to review the current treatment pathways for myelofibrosis from across the UK	No		15/11/2017	19/02/2018	13/11/2017	12/02/2018	14/02/2018	20/02/2018		Neither
17/EE/0177	220722	HRA Approval	BOSTON: A Phase 3 Randomized, Controlled, Open-Label Study of Selinexor, Bortezomib, and Dexamethasone (SVD) Versus Bortezomib and Dexamethasone (VD) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)	No		31/10/2017	02/03/2018	24/07/2017	28/02/2018	13/03/2018	16/03/2018		Neither
18/EM/0005	236933	HRA Approval	AMG 20150136: An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practices	No		14/12/2017	15/12/2017	30/01/2018	20/02/2018	23/02/2018	16/03/2018	sub-contract delays from partner Trust	Neither

Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
16/LO/2195	219516	HRA Approval	TRITON 2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency	No		31/05/2017	31/05/2017	28/03/2017	01/02/2018	12/02/2018	23/03/2018	complex financial and contract negotiations, internal capacity issues to support	Both
17/EM/0120	222298	HRA Approval	TRITON 3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency	No		31/05/2017	31/05/2017	30/06/2017	01/02/2018	12/02/2018	23/03/2018	complex financial and contract negotiations, internal capacity issues to support	Both
17/NW/0718	231114	HRA Approval	CA209-8A7: Early access to medicines scheme ? Nivolumab ? for gastric and Gastroesophageal Junction (GC/GEJ) Adenocarcinoma Observational Study	No		12/03/2018	14/03/2018	22/12/2017	20/03/2018	21/03/2018	23/03/2018		Neither
17/SC/0228	219158	HRA Approval	JAVELIN H&N (B9991016): A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONT LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK	No		01/11/2017	06/11/2017	24/07/2017	16/02/2018	22/02/2018	27/03/2018	complex financial and contract negotiations, internal capacity issues, delays in RTQA	Both
17/LO/0497	220229	HRA Approval	IMCGP100-202: A PHASE II RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF IMCGP100 COMPARED WITH INVESTIGATOR'S CHOICE IN HLA-A*0201 POSITIVE PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED UVEAL MELANOMA	No		26/06/2017	26/06/2017	14/11/2017	07/02/2018	12/02/2018	28/03/2018	Costing queries, internal capacity issues & sub-contract delays from partner Trust	Both
16/YH/0157	204585	HRA Approval	PLATO - Personalising Anal cancer radioTherapy dose	No		03/04/2017	03/04/2017	20/07/2016	06/03/2018	12/02/2018	Project in set-up	RTTQA delays in planning and set-up	NHS Provider
16/LO/0592	179775	HRA Approval	Phase III randomised trial of immunomodulatory therapy in high risk solitary bone plasmacytoma	No		07/06/2017	07/06/2017	09/08/2016			Project in set-up	RTTQA delays in planning and set-up	NHS Provider
17/LO/2024	231946	HRA Approval	LUCY - Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations	No		31/08/2017	31/08/2017				Project in set-up	Awaiting patient pathway confirmation from PI	NHS Provider
12/LO/0515	95626	HRA Approval	Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis	No		07/09/2017	07/09/2017	03/08/2016			Project in set-up	Awaiting study documentation from internal service departments	NHS Provider
17/NW/0369	225797	HRA Approval	PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, RANDOMIZED STUDY OF PRACINOSTAT IN COMBINATION WITH AZACITIDINE IN PATIENTS ≥18 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA UNFIT FOR STANDARD INDUCTION CHEMOTHERAPY	No		01/07/2017	19/09/2017	15/09/2017			Project in set-up	Sub-contract delays from partner Trust	Neither

Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
17/NW/0330	222996	HRA Approval	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation	No		12/09/2017	21/09/2017				Project in set-up	Internal capacity issues by support service: complicated contract & financial negotiations	Both
17/LO/1875	219487	HRA Approval	Renal Adjuvant Multiple Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage multi-centre randomised-controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.	No		10/11/2017	10/11/2017				Project in set-up	Awaiting PI confirmation of capacity to conduct study	NHS Provider
17/NW/0512	221775	HRA Approval	PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma	No		05/10/2017	13/11/2017	08/11/2017			Project in set-up	sub-contract delays from partner Trust	Neither
17/LO/1869	230951	HRA Approval	A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer	No		19/11/2017	19/11/2017				Project in set-up	Awaiting patient pathway confirmation from PI	NHS Provider
16/LO/0877	202257	HRA Approval	A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB* (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WHO COMPLETED FIRST-LINE CHEMOTHERAPY FOR UNRESECTABLE LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER	No		24/11/2017	29/11/2017	05/09/2016			Project in set-up	Internal capacity issues by support service: ARSAC delays (new process)	Both
17/EE/0034	218200	HRA Approval	A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents	No		29/11/2017	05/12/2017	19/06/2017			Project in set-up	sub-contract delays from partner Trust	Neither
	235534	HRA Approval	A phase Ib/Ila, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of Cx611 expanded allogeneic adipose-derived stem cells (eASCs) for the intravenous treatment of adult patients with a severe community-acquired bacterial pneumonia and admitted to the intensive care unit. SEPCELL study.	No		05/12/2017	15/12/2017				Project in set-up	sub-contract delays from partner Trust	Neither
	236687	HRA Approval	Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials	No		08/01/2018	08/01/2018				Project in set-up	Internal capacity issues by support service	NHS Provider

Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
18/SC/0015	236685	HRA Approval	A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-III A and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer(NSCLC)	No		21/12/2017	08/01/2018				Project in set-up	Complicated patient pathway and change over of nursing staff	NHS Provider
14/SC/1346	151280	HRA Approval	National?Lung?Matrix?Trial:?Multi-?drug,?genetic?marker-directed, non?-comparative, multi-?centre, multi?-arm phase II trial in non-small cell lung cancer	No		12/01/2018	12/01/2018	15/07/2017			Project in set-up	sub-contract delays from partner Trust	Neither
17/EM/0338	229242	HRA Approval	A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	No		28/07/2017	26/01/2018				Project in set-up		
17/SC/0661	227234	HRA Approval	Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge) for post chemo-radiotherapy surveillance in patients with oesophageal cancer ? a feasibility study	No		18/12/2017	26/01/2018	23/01/2018			Project in set-up		
17/NW/0634	209375	HRA Approval	A randomized double blind placebo controlled Phase II clinical trial of Cediranib and Olaparib maintenance in advanced recurrent Cervical Cancer.	No		29/01/2018	29/01/2018				Project in set-up		
14/NE/1240	163350	HRA Approval	A RANDOMIZED, DOUBLE-BLIND PHASE 1B/2 STUDY OF PF-04449913 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED INTERMEDIATE-2 OR HIGH-RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA WITH 20-30% BLASTS AND MULTI-LINEAGE DYSPLASIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA	No		03/02/2018	03/02/2018	06/03/2018			Project in set-up		
18/LO/0651	240503	HRA Approval	A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy	No		08/02/2018	08/02/2018				Project in set-up		
18/NW/0031	230387	HRA Approval	A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of nanoliposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (NEC)	No		12/02/2018	12/02/2018				Project in set-up		

Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
17/YH/0187	218853	HRA Approval	A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma	No		22/02/2018	22/02/2018	11/10/2017			Project in set-up		
17/WA/0111	225522	HRA Approval	A Phase III, multicenter, randomised controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy (HATCY study)	No		25/09/2017	02/03/2018				Project in set-up		
18/LO/0352	237528	HRA Approval	A Randomized, Global, Open-Label Study of Nivolumab in Combination with BMS-986205 vs Standard of Care Extreme chemotherapy in first-line recurrent/metastatic squamous cell carcinoma of the head and neck	No		21/02/2018	08/03/2018				Project in set-up		
15/SC/0103	154496	HRA Approval	A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/-nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer	No		14/02/2018	31/03/2018	26/07/2016			Project in set-up		